Abstract
To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer’s disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Mark
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
